PIPages
Labs

Andrew Ludlow

University of Michigan, MI·Physiology

Aging is the biggest risk factor for cardiovascular disease and for cancer. Both diseases share common drivers: failing mitochondria (the cell's power plants), damage from reactive oxygen species, unstable DNA and chronic inflammation.

Fields

Physiology

Genetics

Biology

Topics

telomerase

alternative splicing

splice variants

Grants
1 known grant, through Apr 2027

What they work on

  1. Generate transgenic rats expressing full-length TERT or the catalytically inactive β-del-TERT splice variant to test whether TERT's mitochondrial functions protect tissues independent of telomere lengthening.
  2. Compare the new transgenic rats with wild-type and TERT knockout rats for mitochondrial function, DNA damage, telomere-associated damage foci and senescence markers in liver, intestine, muscle, heart and brain.
  3. Test whether β-del-TERT is sufficient to cause mitochondrial dysfunction that impairs endothelial cell dilation in blood vessels and accelerates cardiovascular disease progression.
  4. Determine whether β-del-TERT shifts the blood-forming (hematopoietic) system toward myeloid cells, altering macrophage polarization and increasing inflammatory stress.

More about the research

Telomerase reverse transcriptase (TERT) is best known for lengthening telomeres, the protective caps on chromosome ends. TERT also works in mitochondria, where it can protect cells from stress. Cells make several versions of TERT through alternative splicing, which cuts and joins the gene's message in different ways. No animal model yet exists to study what these versions do in the body.

Why it matters

Cardiovascular disease and cancer both rise sharply with age. By testing whether TERT's protective work in mitochondria slows aging-related damage, this work could point to molecular or drug strategies that restore TERT's protective functions. It also offers a rat model that other researchers could use to study TERT splice variants in aging and disease.

Known grants

From NIH and NSF research grants. Labs often have other funding we can't see.

Development of a Rat Model to Investigate the Physiology of Telomerase Reverse Transcriptase alternative splicing isoforms

NIH · May 2025 – Apr 2027

Closest labs

Charles Reynolds

Texas Tech University Health Sciences Center, TX·Medicine & Clinical Research

Test whether telomere dysfunction drives high ATM kinase activation, a DNA-damage alarm signal, across ALT+ cancers of many types, using patient-derived cell lines and mouse xenografts compared with telomerase+ models.

Aditi Gurkar

University of Pittsburgh, PA·Medicine & Clinical Research

Map how oxidative 8-oxoguanine damage at telomeres signals to mitochondria to drive senescence in human iPSC-derived cardiomyocytes and cardiac fibroblasts, using a light-activated chemoptogenetic tool that damages only telomeres.

Mary Armanios

Johns Hopkins University, MD·Genetics

Identify additional large-effect inherited variants that cause long telomere syndromes in cancer-prone families, extending beyond the POT1 mutations and the two other telomere genes already found to phenocopy them.

The school

University of Michigan: 124 labs on PI Pages, $2.1B a year on research, 963 research doctorates a year.

More about University of Michigan

Reach out

A start for your email. Fill in the brackets.